candesartan has been researched along with CACH Syndrome in 2 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan treatment alleviated matrisome protein accumulation and normalized the vascular distensibility and cerebral blood flow." | 1.62 | Candesartan prevents arteriopathy progression in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy model. ( Ando, S; Fujita, N; Fukunaga, M; Hasegawa, M; Hatano, Y; Hirokawa, S; Igarashi, H; Ihara, M; Kakita, A; Kametani, F; Kanazawa, M; Kato, T; Kawashima, Y; Kawata, H; Koyama, A; Manabe, RI; Matsumoto, M; Murayama, S; Nishizawa, M; Nozaki, H; Onodera, O; Saito, R; Saito, S; Sato, T; Sekine, Y; Sugai, A; Sugie, A; Toyoshima, Y; Tsuji, S; Uemura, M, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, T | 1 |
| Manabe, RI | 1 |
| Igarashi, H | 1 |
| Kametani, F | 1 |
| Hirokawa, S | 1 |
| Sekine, Y | 1 |
| Fujita, N | 1 |
| Saito, S | 1 |
| Kawashima, Y | 1 |
| Hatano, Y | 1 |
| Ando, S | 1 |
| Nozaki, H | 1 |
| Sugai, A | 1 |
| Uemura, M | 1 |
| Fukunaga, M | 1 |
| Sato, T | 1 |
| Koyama, A | 1 |
| Saito, R | 1 |
| Sugie, A | 1 |
| Toyoshima, Y | 1 |
| Kawata, H | 1 |
| Murayama, S | 1 |
| Matsumoto, M | 1 |
| Kakita, A | 1 |
| Hasegawa, M | 1 |
| Ihara, M | 1 |
| Kanazawa, M | 1 |
| Nishizawa, M | 1 |
| Tsuji, S | 1 |
| Onodera, O | 1 |
| Hounoki, H | 1 |
| Shinoda, K | 1 |
| Taki, H | 1 |
| Ogawa, R | 1 |
| Sugiyama, E | 1 |
| Tobe, K | 1 |
2 other studies available for candesartan and CACH Syndrome
| Article | Year |
|---|---|
Candesartan prevents arteriopathy progression in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy model.
Topics: ADAMTS Proteins; Alopecia; Animals; Benzimidazoles; Biphenyl Compounds; Cerebral Infarction; Cerebro | 2021 |
Reversible posterior leukoencephalopathy syndrome in a patient with systemic sclerosis.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Captopril; Female; Humans; Leuko | 2011 |